On the same day as its emergence from stealth mode, Dyno Therapeutics has signed collaboration agreements with Novartis and Sarepta Therapeutics in deals potentially worth over US$2 B combined. The deals will utilise Dyno’s CapsidMap™ artificial intelligence platform to design and develop adeno-associated virus capsids with improved functional properties for gene therapies in the treatment of ocular diseases with Novartis, and muscle diseases with Sarepta. The partnering companies will be responsible for conducting preclinical, clinical and commercialisation activities for gene therapy product candidates using the capsids.